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Pharmacokinetics of Torsemide in Patients
with Decompensated and Compensated
Congestive Heart Failure
Barry E. Bleske, PharmD, FCCP, Lynda S. Welage, PharmD, William G. Kramer, PhD,
and John M. Nicklas, MD
Plasma pharmacokinetics of oral furosemide have been
shown to be influenced by degree of decompensation in
patients with congestive heart failure (CHF). This open-label,
sequential comparison trial was conducted to determine
whether Cl-IF decompensation also alters the pharmacoki-
netics and pharmacodynamics of torsemide. Twelve patients
with CHF, defined by either hemodynamic parameters or
clinical signs and symptoms, were enrolled. On admission
for treatment of their CHF, the patients were given 100 mg
oral torsemide (phase A). A second dose of oral torsemide
100 mg was administered after hemodynamic parameters
and clinical signs and symptoms of decompensated Cl-IF
resolved (phase B). Plasma and urine samples were collected
over a 24-hour period for determination of torsemide con-
centrations and urine sodium. Hemodynamic measurements
and physical signs and symptoms also were evaluated. Dur-
ing phase A, patients had significantly greater urine output
and fractional sodium excretion compared with phase B. A
significant increase in the area under the plasma concentra-
tion-time curve (A UC) was observed during phase B com-
pared with phase A. However, no significant differences in
maximal excretion rate of torsemide were noted between
phase A and phase B. Heart failure status slightly affects the
plasma pharmacokinetics of torsemide; however, this does
not significantly alter the maximal urinary excretion rate of
torsemide.
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E dema associated with congestive heart failure
(CHF) is difficult to manage because patients of-
ten have altered response to orally administered di-
uretics. These changes may be due in part to alter-
ations in the pharmacokinetics of loop diuretics in
decompensated and compensated heart failure. A
previous study has demonstrated that both the rate
of absorption and the pharmacodynamic effect of
furosemide differs significantly between patients
with compensated and decompensated CHF.1 Alter-
ations in drug absorption may be the result of
changes in gastrointestinal physiology (i.e., delayed
gastric emptying, edema, and decreased gastrointes-
tinal motility) that occur in GHF. The change in
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diuretic efficacy may relate to changes in urinary
excretion of drug, intravascular volume, and diet.
Regardless of the mechanism, the variation in these
parameters between patients with compensated and
those with decompensated disease makes effective
treatment of edema in CHF challenging.
Torsemide is a loop diuretic of the pyridine sulfo-
nylurea class approved for the treatment of edema in
patients with CHF. Recent data suggest that the bio-
availability of torsemide in a variety of edematous
disease conditions, including chronic renal insuffi-
ciency, cirrhosis, and CHF, is equal to or greater than
that observed in healthy volunteers.2_4 In addition,
there is less variability in the bioavailability of
torsemide than in that of furosemide in patients with
CHF.4 These data suggest that torsemide achieves
consistent concentrations of drug in the body across
a variety of edematous disease conditions and may
theoretically provide consistent drug concentrations
in patients with both compensated and decompen-
sated GHF.
We performed this study to determine if the phar-
macokinetics and pharmacodynamics of torsemide
are influenced by a patient’s heart failure status (de-
compensated versus compensated). The results from
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this study will help determine if torsemide offers
any potential advantage for the treatment of GHF.
PATIENTS AND METhODS
A total of 12 patients completed an open-label se-
quential trial evaluating the pharmacokinetic and
pharmacodynamic properties of torsemide in de-
compensated (phase A) and compensated GHF
(phase B). All patients had been hospitalized for
treatment of GHF at the University of Michigan
Health System in Ann Arbor. After approval from
the hospital Institutional Review Board and before
study entry, informed consent was obtained from
each patient. Inclusion criteria for the study in-
cluded a confirmed diagnosis of chronic CHF ( 3
months), a New York Heart Association Glassifica-
tion of III or IV, systolic dysfunction defined as a left
ventricular ejection fraction  40% measured within
the past year, and an etiology of GHF secondary to
ischemic, idiopathic, or noncritical valvular disease.
In addition, study patients had to have evidence of
congestion and decompensation defined by physical
and/or hemodynamic abnormalities as follows: 1)
Physical evidence of congestion, including pitting
edema  2 mm in the lower extremities extending
from the ankles to mid-calf and rales on pulmonary
examination; and 2) hemodynamic evidence of con-
gestion, including pulmonary capillary wedge pres-
sure  25 mmHg and right atrial pressure  10
mmHg.
Hemodynamic measurements were performed by
placement of a pulmonary artery catheter whose
placement was verified by waveform evaluation. Ex-
clusion criteria included serum creatinine  3
mg/dL, serum bilirubin  2 mg/dL, requirement for
a nonsteroidal antiinflammatory agent (with the ex-
ception of low dose aspirin, up to 325 mg/day) or
probenecid, and GHF secondary to nondilated car-
diomyopathy or hemodynamically significant ste-
notic valvular disease.
All participants were inpatients admitted to the
hospital for the treatment of GHF. On admission,
baseline blood and urine samples were obtained,
including predose samples for measurement of
plasma and urine torsemide concentrations. After
the baseline samples were obtained, phase A of the
study was initiated with oral administration of
torsemide 100 mg with 120 mL of water. Plasma
samples were collected from a forearm venous cath-
eter into heparmnized vacutainer tubes (Becton Dick-
inson, Rutherford, NJ) before and 0.25, 0.5, 0.75, 1.0,
1.25, 1.5, 1.75, 2.0, 2.25, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0,
and 24.0 hours after drug administration. Urine sam-
ples were collected and analyzed for torsemide, so-
dium, and creatinine concentrations before and for
the intervals from 0 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 6,
6 to 8, 8 to 12, and 12 to 24 hours after administra-
tion. After the last sample was obtained, further di-
uresis was achieved with either bumetanide or furo-
semide administered orally or intravenously, as
indicated based on the patient’s clinical status.
For the second phase of the study (phase B),
torsemide 100 mg was administered orally with 120
mL of water after the resolution of the signs of con-
gestion, as evidenced by the following: 1) a decrease
in body weight  5 pounds; and 2) resolution of the
physical findings of congestion or a decrease in he-
modynamic abnormalities, including resolution of
the physical findings of congestion including pe-
ripheral edema and rales on pulmonary examination
and a decrease in the hemodynamic abnormalities of
congestion defined as a decrease of  10 mmHg in
pulmonary capillary wedge pressure or to an abso-
lute pulmonary capillary wedge pressure 18
mmHg and a decrease in right atrial pressure to an
absolute pressure 8 mmHg.
For the second phase of the study, time of food
intake and concomitant drug administration were
reasonably matched to those of the first phase. The
time of torsemide administration was also matched
(within a 4-hour time period) to the first phase.
Plasma and urine measurements were obtained at
the same time points as for the first phase. In patients
who showed a minimal response to administration
of torsemide during the first phase, the study was
terminated no sooner than the 6-hour collection time
point. In these cases, data collection time points for
the second phase were matched to the first phase.
Drug Analysis
Plasma and urine concentrations of torsemide were
measured by a high-performance liquid chromatog-
raphy (HPLG) method that has been previously de-
scribed and validated. The interday and intraday
coefficient of variation over a linear range of 50 to
2,000 ng/mL was less than 10% for determination of
both plasma and urine concentrations of torsemide.
Data Analysis
Pharmacokinetic parameters were determined by
noncompartmental methods and inspection of the
data where appropriate. Specifically, the area under
the plasma concentration-time curve (AUC) to the
last measured time point was determined by the
linear trapezoidal method with extrapolation to in-
finity. The elimination half-life (t!) was determined
by linear regression analysis of the terminal phase of
the log concentration-time profile. The maximal
plasma concentration (Cmax) and time to Cmax (tinax)
were determined by inspection of the available data
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Table I Mean Clinical Parameters in Patients with
Decompensated (Phase A) and Gompensated
(Phase B) Congestive Heart Failure
Parameter Phase A Phase B
Weight (kg) 84.1 ± 22.2 79.5 ± 21.0*
RAP (nimHg) 13.1 ± 3.9 3.9 ± 2.1*
PAS (mmHg) 64.7 ± 10.8 32.6 ± 8.7*
PAD (mml-Ig) 35.3 ± 4.5 16.2 ± 5.0*
PCWP (mmHg) 36.3 ± 3.8 12.2 ± 3.8*
BPS (mmHg) 110 ± 14 103 ± 5
BPD (mmHg) 74 ± 11 69 ± 6
HR (beats/mm) 93 ± 14 84 ± 12
Clcr (mL/min) 88 ± 31 75 ± 23*
* P < 0.05 versus phase A.
RAP, right atrial pressure; PAS, pulmonary artery systolic pressure; PAD,
pulmonary capillary diastolic pressure; PCWP, pulmonary capillary wedge
pressure; BPS, systolic blood pressure; BPD, diastolic blood pressure; HR.
heart rate; clcr, creatinine clearance.
Values are presented as mean ± standard deviation.
by dividing area under the first moment curve (de-
termined by the linear trapezoidal method) by the
area under the plasma concentration-time curve
from zero to infinity. Renal clearance (Clr) was cal-
culated as the total amount of unchanged drug ex-
creted into the urine (Ae) divided by the AUG to the
last measured collection. The urinary excretion rate
of torsemide over each collection interval was cal-
culated by dividing the amount of torsemide ex-
creted during the interval by the duration of the
period. The maximum excretion rate (ERm,) was
determine by visual inspection of the data. Creati-
nine clearance and the natriuretic response, as as-
sessed by fractional sodium excretion (Fena), were
determined based on urinary concentrations and
standard formulas.
Statistical comparison between the two phases
was performed by a paired t-test. P  0.05 was con-
sidered the critical probability level. The reported
data are represented as the mean ± standard devia-
tion.
RESULTS
A total of 14 patients were enrolled in the study,
with 12 patients completing both phases. Two pa-
tients were excluded, one secondary to receiving
probenecid and the other secondary to nausea and
vomiting after receiving the first dose of torsemide.
The urine data for one patient was excluded from
analysis based on inadequate urine collection during
the study period. Therefore, plasma data from 12
patients were used for analysis, whereas for analysis
of the urine data, only 11 of the 12 patients were
evaluated. Eight men and four women were included
in the study, with a mean age of 53.5 ± 9 years and
a mean ejection fraction of 23 ± 7%. Of the patients
who completed the study, nine qualified for the
study according to hemodynamic measurements and
three qualified based on clinical observations.
Mean clinical parameters for phase A and phase B
are shown in Table I. Significant differences between
phase A and phase B were noted for weight and
hemodynamic measurements. No significant differ-
ences were noted for heart rate and blood pressure.
However, creatinine clearance was significantly di-
minished during phase B compared with phase A. Of
the 12 patients, 8 (67%) had a decrease in creatinine
clearance between phase A and phase B (Figure 1).
In addition, significant differences were also noted
for both serum creatinine and blood urea nitrogen to
serum creatinine ratio between phase A and B (1.1 ±
0.04 versus 1.6 ± 0.05 mg/dL, P < 0.03, and 16.8 ±
1.9 versus 22.1 ± 2.9, P < 0.02, respectively). A total
of 10 of the 12 patients had increases in both param-
eters from phase A to phase B.
Mean pharmacokinetic parameters for plasma con-
centrations of torsemide are shown in Table II, and
the mean concentration-time profiles are displayed
in Figure 2. The mean AUG value was significantly
higher during the compensated stage (phase B) than
Figure 1. Change in creatinine clearance between Phase A (de-
compensated) and Phase B (cam pensated)for individual patients.
Each symbol represents an individual patient. The mean is indi-
cated by the closed circles.
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Table II Mean Pharmacokinetic Data for Patients
with Decompensated (Phase A) and Compensated
(Phase B) Congestive Heart Failure
Parameter Phase A Phase B
Crn*x (.tg/mL) 10.1 ± 3.4 12.7 ± 4.6
tmax (hrs) 2.7 ± 3.0 1.5 ± 0.6
AUC (hr .sg/mL) 39.9 ± 13.0 47.2 ± 18.1*
t1,2 (hrs) 4.2 ± 1.2 4.3 ± 1.3
MRT (hrs) 5.87 ± 1.9 5.5 ± 1.7
Cl 7.2 ± 3.2 4.6 ± 2.5*
Ae (% dose) 16.1 ± 9.0 12.1 ± 6.5
ER0,,,,. (tg/hr) 3729 ± 2087 3378 ± 1556
* P < 0.05 versus phase A.
Values are presented as the mean ± standard deviation.
cm,,,,, maximal plasma concentration; tm,,,,, time to cm,,,,; AU(, area under
the concetration-time curve; 11,2, half-life; MRT, mean residence time; dr.
renal clearance; Ae, unchanged drug excreted into the urine; ERm,.,, max-
imum urinary excretion rate.
in the decompensated stage (phase A). Although
mean Gmax was higher and mean tmax shorter during
phase B compared with phase A, these differences
were not statistically significant. The longer tmax dur-
ing phase A is somewhat skewed because one pa-
tient had a tmax of 12 hours. Exclusion of this data
point shows an average tmax of 1.87 ± 0.62 hours
(range 0.75-2.5 hours), which is similar to the tmax of
1.54 ± 0.62 hours observed during phase B (range
1-3 hours). No statistical differences were noted for
the other parameters.
Data regarding urinary excretion of torsemide are
shown in Table II. The mean urinary excretion rate
time profile of torsemide for each treatment phase is
depicted in Figure 3. The maximal urinary excretion
rate for torsemide was similar between phase A and
phase B. Renal clearance of torsemide was signifi-
cantly higher during the decompensated phase.
Regarding pharmacodynamic response, the maxi-
mal fractional sodium excretion and total sodium
was significantly higher for phase A than for phase B
(5.6 ± 1.9% versus 3.4 ± 1.8% and 73.6 ± 51 mEq/hr
versus 26.6 ± 20.2 mEq/hr, respectively; P < 0.03).
Overall sodium excretion during the study period
was higher during phase A than during phase B
(272 ± 139 mEq versus 89 ± 57 mEq, respectively; P
<0.002; Figure 4). In conjunction with the effect on
sodium excretion, urine volumes during the study
period were also significantly greater during phase A
than during phase B (3,338 ± 1,244 mL versus
1,903 ± 688 mL, respectively; P < 0.0007).
DISCUSSION
This study demonstrated that the plasma pharmaco-
kinetics and pharmacodynamic effect of orally ad-
ministered torsemide were altered by degree of de-
compensation in patients with CHF. Based on the
plasma pharmacokinetics, one would predict that
the pharmacodynamic response would be lower dur-
ing the decompensated state than the compensated
state; however, the urinary pharmacokinetic data
suggests the opposite. The urinary pharmacokinetic
parameters, including renal clearance, were higher
during the decompensated phase than during the
compensated phase, and this may explain the greater
pharmacodynamic response (i.e., high urine output,
FeNa, etc) that was observed during the decompen-
sated state. Differences in pharmacodynamic re-
sponses between the two study phases may also be
explained in part by alterations in physiology that
occur secondary to changes in intravascular volume.
Although there was a slight increase in Gmax and a
slight decrease in tmax during the compensated
phase, no statistically significant differences were
detected between the two study phases. Specifically,
10 of the 12 patients had an increase in Cmax and 9 of
12 patients had a decrease in truax during the com-
pensated phase. The lack of statistical significance
between the two phases may be the result of a type II
error. Overall, the data suggest that the absorption of
torsemide maybe slightly slower in some patients
during the decompensated state. However, the rela-
tively minor changes in Gmax and tmax are of ques-
tionable clinical importance.
A previous study in which furosemide was admin-
istered to patients with decompensated and compen-
sated GHF (based on clinical signs and symptoms)
suggests an alteration in absorption.1 Specifically,
statistically significant differences were observed for
Gmax and tmax values between the two phases. The
degree of alteration in tmax and Cmax between decom-
pensated and compensated states observed with fu-
rosemide was similar to that observed in this study.
Overall, the clinical significance of these changes are
most likely dependent on the dose used. The precise
mechanism responsible for this altered absorption
for both drugs is not known, but may relate to
changes in gastrointestinal physiology (i.e., delayed
gastric emptying, edema, and decreased gastrointes-
tinal motility) that may occur during the decompen-
sated phase of GHF, or to changes in volume of
distribution.
There was an increase in AUC during the compen-
sated phase compared with the decompensated
phase, with an AUG ratio of 86.4% (decompensated
to compensated). The increase in AUG after compen-
sation may be related to changes in absorption
(Gmax), renal clearance, total clearance, or even vol-
ume of distribution (secondary to fluid changes).
Although we can not definitively identify which of
the above factors are responsible for the change in
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Figure 2. Mean torsemide plasma
concentration-time curve in pa-
tients with decompensated (Phase
A) and compensated (Phase B)
heart failure.
study is unlikely to be the sole contributing factor.
Renal clearance accounts for no more than 25% of
total torsemide clearance in subjects with normal
kidney function,2 and thus the change in renal clear-
ance observed in this study would not predict the
change seen in AUG. A decrease in total clearance
could also lead to an increased AUG. To definitely
determine if the extent of absorption is affected or if
there is a change in clearance, administration of
intravenous torsemide is required.
For torsemide to exert its effect, drug must reach
the urine, because the site of action for a loop di-
uretic is the luminal side of the tubule.6 Therefore,
alterations in the pharmacokinetic parameters of
Figure 3. Mean urinary concentra-
tion-time curve of torsemide in pa-
tients with decompensated (Phase
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Figure 4. Mean urinary sodium ex-
cretion versus time in patients
with decompensated (Phase A)
and compensated (Phase B) heart
failure.
torsemide in plasma observed between the two
phases may not be clinically important, because the
pharmacokinetic parameters for urinary concentra-
tions of torsemide were similar between the two
phases. Specifically, the total amount of drug ex-
creted in the urine, the urinary excretion rate time
profile, and the maximal excretion rate of torsemide
were similar between the phases (Figure 3). What
influence the change in creatinine clearance has on
these results is not certain.
The correlation between renal clearance of drug
and creatinine clearance was statistically significant
but was not equal to one (r2 = 0.29; P < 0.05). In
addition, the mean percent change in creatinine
clearance between the two phases was less than
20%. These findings suggest that the change in cre-
atinine clearance between the two phases probably
had an effect on our results, including on the renal
clearance of torsemide, but that these effects were
minimal. In other words, urinary concentrations of
torsemide would have been similar between the two
phases even if there was no statistical difference in
creatinine clearance. However, despite our conjec-
tures, we cannot rule out that our findings are di-
rectly related to the change in creatinine clearance
observed between the two phases. Theoretically, uri-
nary concentrations of torsemide may have been
greater in phase B if it were not for the observed
change in creatinine clearance.
The diuretic effect of torsemide was greater during
the decompensated phase than during the compen-
sated phase of this study. Specifically, urine vol-
umes, total sodium excretion, and maximal sodium
excretion rate were greater during phase A than dur-
ing phase B. Fractional excretion of sodium was
evaluated to account for differences in creatinine
clearance between the two phases. The reason for the
diminished response seen in phase B is not clear, but
probably relates to what has been described in pre-
vious trials as a “braking” effect.1,7_9 The mechanism
for this temporary condition is not certain, but may
relate to physiologic responses that occur secondary
to changes in intravascular volume. The clinical sig-
nificance of this “braking” effect is important, espe-
cially with regard to prescribing adequate doses of
diuretics on discharge from the hospital. Clinicians
need to be cognizant of the diminished diuretic re-
sponse before discharge and provide appropriate
conversion from intravenous to oral formulations
with an adequate time period for observation.
A potential limitation of this study is whether or
not there was a significant difference in fluid status
between the two phases. As shown in Table I, sig-
nificant differences were observed in intravascular
pressures and weight, which suggests that significant
differences were obtained. Another consideration is
whether the time between the two phases was suffi-
cient to allow for changes in gastrointestinal physi-
ology to occur. The interval between the two phases
(5.3 ± 3.2 days) was similar to that in the previously
mentioned furosemide study, in which alterations in
pharmacokinetic parameters were observed.
Overall, the results from this study suggest that the
plasma pharmacokinetics and effect of torsemide
BLESKE ET AL
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may depend on a patient’s heart failure status. How-
ever, the difference in the plasma pharmacokinetic
parameters of torsemide between patients with de-
compensated and compensated heart failure do not
appear to significantly effect the maximal urinary
excretion rate of torsemide. This suggests that any
change in the clinical response to torsemide between
the decompensated and compensated stages of CHF
at the dose studied is probably not related to phar-
macokinetic alterations.
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